Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas

Overview of attention for article published in Oncotarget, July 2016

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 36 news outlets
twitter: 2 X users

facebook: 1 Facebook page
f1000: 1 research highlight platform

Readers on

mendeley: 75 Mendeley

So far, Altmetric has seen 38 news stories from 36 outlets.

Castle Biosciences Announces Launch of New Eye Cancer Test to Measure Expression of...

Fresh News, 10 Oct 2016

PRAME expression, when combined with DecisionDx-UM test results, correlates with increased risk of metastasis in patients with…

Castle Biosciences Announces Launch of New Eye Cancer Test to Measure Expression of PRAME Gene

News Channel, 10 Oct 2016

PRAME expression, when combined with DecisionDx-UM test results, correlates with increased risk of metastasis in patients with…

Castle Biosciences Announces Launch of New Eye Cancer Test to Measure Expression of PRAME Gene

News Channel 10, 10 Oct 2016

PRAME expression, when combined with DecisionDx-UM test results, correlates with increased risk of metastasis in patients with…

Castle Biosciences Announces Launch of New Eye Cancer Test to Measure Expression of PRAME Gene

KUSI News, 10 Oct 2016

PRAME expression, when combined with DecisionDx-UM test results, correlates with increased risk of metastasis in patients with…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 34 additional news stories.